Two treatments for Ebola which were undergoing trials in the Democratic Republic of Congo have been stopped early due to their success in treating Ebola. The two treatments will now be made widely available. One of the drugs is REGN-EB3, a cocktail of three monoclonal antibodies developed by Regeneron Pharmaceuticals. The other drug is mAb114, which is now being developed with Ridgeback Biotherapeutics.
Importing the Ebola virus and other infectious diseases is intended to help strengthen Japan’s inspection system for diseases that have never spread within the country, in preparation for an expected increase in visitors from abroad ahead of the 2020 Tokyo Olympic and Paralympic Games.
The 2018 Ebola virus disease outbreak in Équateur Province, Democratic Republic of the Congo, began on May 8, and was declared over on July 24. Researchers did a retrospective genomic characterization of the outbreak and assessed potential therapeutic agents and vaccines.
The Ebola virus causes a disease that kills up to 90 percent of those who contract it, but a promising vaccine could provide protection.
This study provides the first evidence of Ebola virus-infected survivors from the index site of the west African outbreak. A thorough retrospective epidemiological study done concomitantly among the resident adult population expands understanding of the initiating events including transmission dynamics, probable transmission chains, lower case fatality rates, and the presence of both mild and asymptomatic cases.
A detailed analysis of blood samples from Ebola patients in Sierra Leone is providing clues about the progression of the effects of the Ebola virus in patients and potential treatment pathways. The findings point to a critical role for a molecular pathway that relies on the common nutrient choline, as well as the importance of cellular bodies known as microvesicles.
This National Ebola Training and Education Center course discusses the assessment, management, and placement of persons suspected to have Ebola and Other Special Pathogens.
.This course facilitates learners to describe pathogen-related factors that may warrant treatment in a biocontainment unit and to distinguish between concepts of infectious, communicable, and hazardous as they relate to Ebola and other special pathogens of concern. Participants will also be able to describe the clinical presentation of selected special pathogens from the two broad categories: viral hemorrhagic fevers and the highly pathogenic respiratory viruses.
A team of researchers have discovered the interaction between an Ebola virus protein and a protein in human cells that may be an important key to unlocking the pathway of replication of the killer disease in human hosts.